APEPTICO Announces Successful Completion of Phase I Trial with AP301 in Oedematous Respiratory Failure
01-Nov-2011 -
APEPTICO GmbH announced completion of a Phase I clinical trial for its pulmonary sodium ion channel activator AP301. The orally inhaled drug candidate was safe and well-tolerated by all study participants. AP301 is being developed for the prevention and treatment of oedematous respiratory failure ...
APEPTICO
clinical trials
ion channels
+1